Pharmaceutical outsourcing project name: Chlorambucil paper matrix tablets
Pharmaceutical outsourcing project name: CHLORAMBUCIL CHART TABLETS
want to find a (CRO) Contract Research Organization Location: any
Drugs (CRO) Contract Research description:
Pharmaceutical outsourcing categories: alkylating antineoplastic
Pharmacokinetics: Oral absorption completely, bioavailability greater than 70% in 1 hour, the liver up to the highest tissue concentration. Its metabolite phenylacetic acid mustard in 2 ~ 4 hours after treatment in plasma reached the peak plasma concentration and the prototype equivalent half-life of 1 ~ 2 hours, the area under the concentration-time curve of large alkylating agent with a dual-function role. 24 hours 60% of the drug with the urine, of which 90% of the nitrogen mustard chlorambucil and phenylacetic acid hydrolysis of material. Part of the drug molecules are characteristics of the pro-fat, stored in the fat, thereby prolonging the time of the clinical effect of this product.
Properties: This product is white or white paper matrix tablets
Pharmacology and toxicology: The product is a nitrogen mustard derivatives with bifunctional alkylating agent role, can form unstable ethylene imine and play its cytotoxicity, interference with DNA and RNA function. In conventional doses, the toxicity of nitrogen mustard drugs than any other small. Sensitive to the proliferative state of cells, especially for G1 phase and M phase of the role of the strongest, is a cell cycle non-specific drugs. On lymphocytes have a certain role in selective control.

Contraindications: Where there is a serious bone marrow suppression, infection disabled, there is a history of gout, urinary tract stones are used with caution. Those who are allergic to this product is disabled.
Note: This product is longer administration, efficacy and toxicity in the treatment of more than 3 weeks after the emergence of blood and should be closely observed phase change, and pay attention to accumulate.
Pregnant and lactating women medication: This product has mutagenic, teratogenic effects, can cause fetal death or congenital malformations, so pregnant women, disabled.
Medication for children:
Medication in elderly patients:
Drug interactions: not clear.
Indications: mainly used for chronic lymphocytic leukemia, but also can be used for malignant lymphoma, ovarian cancer, multiple myeloma and macroglobulinemia treatment.
Usage and dosage: Daily 0.1 ~ 0.2mg/kg (6 ~ 10mg), or (4 ~ 8mg/m2), day 1 or sub-3 ~ 4 times orally qd for 3 to 6 weeks, a total course of treatment up to 300 ~ 500mg.
Adverse reactions: bone marrow suppression: is a moderate, mainly neutropenia, the impact on platelet lighter, but the dose of medication may occur continuously like a drop of whole blood. Gastrointestinal reactions: mild, mostly anorexia, nausea and occasionally vomiting. Reproductive system response: long-term application of product can be caused by a lack of sperm or lasting infertility, menstrual disorders or menopause. Other rare adverse reactions include the central nervous system toxicity, skin rash, hair loss, liver damage and heat and so on, long-term or high doses can lead to interstitial pneumonia.

[...your have to login read full text ] OR Free Create Account
Search other pharmaceutical contract projects?